Popular Boards
Fredrik Jernerén, Amany Elshorbagy, Abderrahim Oulhaj | American Journal of Clinical Nutrition | (2015)
Abstract
Tags
Sample Definition And Size
The study was a retrospective analysis of data from the VITACOG randomized controlled trial. It included 168 elderly individuals (aged ≥70 years) with mild cognitive impairment, randomly assigned to either a high-dose B vitamin supplementation group (n = 85) or a placebo group (n = 83) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/25877495/?utm_source=openai)).
Study Type
Randomized controlled trial (VITACOG), with retrospective exploratory analysis of interaction between baseline plasma long-chain ω‑3 fatty acid concentrations and B vitamin treatment effect on brain atrophy rates ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/25877495/?utm_source=openai)).
Conflicts Of Interest
No conflicts of interest were declared in the available abstract or metadata ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/25877495/?utm_source=openai)).
Results Summary
There was a significant interaction (P = 0.024) between B vitamin treatment and baseline plasma combined ω‑3 fatty acids (EPA + DHA) on brain atrophy rates. In participants with high baseline ω‑3 fatty acids (>590 µmol/L), B vitamin treatment slowed mean brain atrophy rate by 40% compared with placebo (P = 0.023). No significant effect was observed in participants with low baseline ω‑3 fatty acids (<390 µmol/L) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/25877495/?utm_source=openai)).
Referenced In
RC Yu
2 months ago
Created: Mar 27, 2026